１０名健康男性受试者，分别单次空腹口服国产罗红霉素分散片和国产片剂３００ｍｇ后，用不同时间血中罗红霉素的浓度绘制了血药浓度时间曲线．结果表明：两种制剂中罗红霉素的药物动力学过程均符合二室模型，Ｃｍａｘ（７０２±１７３）μｇ／ｍＬ和（６４７±１２）μｇ／ｍＬ，Ｔｍａｘ为（１０５±０３４）ｈ和（１５０±０４１）ｈ，ｔ１／２（ｋｅ）为（１５８５±２１２）ｈ和（１４０７±２０７）ｈ，ＡＵＣ０→∞为（６８７±１４３）μｇ／ｍＬ·ｈ和（６５６±１４８）μｇ／ｍＬ·ｈ．比较两种制剂动力学参数，两种制剂间罗红霉素的Ｃｍａｘ和ＡＵＣ０→∞均无显著差异，Ｐ＞００５．罗红霉素分散片的平均相对生物利用率为（１０５７±１２０３）％，根据双单侧检验可以认为两种制剂在人体内具有生物等效性． Ten healthy male subjects were given a single fasting oral roxithromycin dispersible tablets and domestic tablets 300mg, with different levels of blood roxithromycin concentration-time curve of blood concentration-time curve. The results showed that the pharmacokinetics of roxithromycin in both preparations were in accordance with two-compartment model with Cmax (702 ± 173) μg / mL and (647 ± 12) μg / mL, Tmax (105 ± 034) h and (150 ± 041) h, t1 / 2 (ke) were (1585 ± 212) h and (07 ± 207) h, AUC0 → ∞ of (687 ± 143) μg / mL · h and (656 ± 148) μg / mL · h. Comparing the kinetic parameters of the two preparations, there was no significant difference in the Cmax and AUC0 → ∞ of roxithromycin between the two preparations, P> 005. The average relative bioavailability of roxithromycin dispersible tablets was (1057 ± 1203)%. According to the double unilateral test, the two preparations could be considered bioequivalent in human.